Arrowstreet Capital Limited Partnership Has $21.94 Million Stock Holdings in Ingevity Corporation $NGVT

Arrowstreet Capital Limited Partnership grew its stake in shares of Ingevity Corporation (NYSE:NGVT) by 331.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 308,046 shares of the company’s stock after purchasing an additional 236,566 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Ingevity were worth $21,942,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Assetmark Inc. raised its holdings in Ingevity by 9.6% during the 1st quarter. Assetmark Inc. now owns 1,584 shares of the company’s stock worth $113,000 after buying an additional 139 shares during the period. Advisory Services Network LLC raised its holdings in shares of Ingevity by 4.4% during the third quarter. Advisory Services Network LLC now owns 6,947 shares of the company’s stock valued at $383,000 after acquiring an additional 293 shares during the period. Amundi lifted its position in shares of Ingevity by 4.8% in the 3rd quarter. Amundi now owns 6,626 shares of the company’s stock valued at $364,000 after acquiring an additional 302 shares in the last quarter. Isthmus Partners LLC lifted its position in shares of Ingevity by 0.5% in the 4th quarter. Isthmus Partners LLC now owns 72,245 shares of the company’s stock valued at $4,275,000 after acquiring an additional 375 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after purchasing an additional 387 shares during the period. Institutional investors and hedge funds own 91.59% of the company’s stock.

Insiders Place Their Bets

In other Ingevity news, SVP Terrance M. Dyer sold 496 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $68.49, for a total value of $33,971.04. Following the transaction, the senior vice president owned 7,202 shares in the company, valued at approximately $493,264.98. This represents a 6.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.88% of the company’s stock.

Ingevity Trading Down 4.6%

NYSE:NGVT opened at $71.08 on Thursday. The stock has a market cap of $2.47 billion, a PE ratio of -20.02 and a beta of 1.16. Ingevity Corporation has a fifty-two week low of $39.74 and a fifty-two week high of $79.29. The company has a debt-to-equity ratio of 27.83, a current ratio of 1.42 and a quick ratio of 0.92. The stock’s 50-day moving average is $71.53 and its two-hundred day moving average is $70.91.

Ingevity (NYSE:NGVT) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.41. The business had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity had a negative net margin of 10.55% and a positive return on equity of 207.82%. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. As a group, equities research analysts forecast that Ingevity Corporation will post 5.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on NGVT shares. Wall Street Zen upgraded shares of Ingevity from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Ingevity in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $80.00.

Ingevity Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.